Kymera Therapeutics (KYMR) Total Non-Current Liabilities (2020 - 2024)

Kymera Therapeutics (KYMR) has 5 years of Total Non-Current Liabilities data on file, last reported at $142.4 million in Q4 2024.

• Total Non-Current Liabilities for Q4 2024 came in at $142.4 million, down 21.22% year-over-year; the trailing twelve-month figure through Dec 2024 was $142.4 million (down 21.22% YoY), and the FY2024 annual result was $142.4 million, down 21.22% from the prior year.
• Total Non-Current Liabilities declined to $142.4 million in Q4 2024 per KYMR's latest filing, from $180.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $203.2 million in Q4 2020 and troughed at $112.7 million in Q4 2022.
• A 5-year average of $153.5 million and a median of $149.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities decreased 29.14% in 2022, then jumped 60.37% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $203.2 million in 2020, then dropped by 28.05% to $146.2 million in 2021, then decreased by 22.89% to $112.7 million in 2022, then jumped by 60.37% to $180.8 million in 2023, then slipped by 21.22% to $142.4 million in 2024.
• Business Quant data shows KYMR's Total Non-Current Liabilities at $142.4 million in Q4 2024, $180.8 million in Q4 2023, and $156.8 million in Q3 2023.